General Data Company Acquires Triangle Biomedical Sciences

Danaher Corporation Acquires Genedata AG

August 19, 2024

Software

Danaher Corporation has acquired Genedata AG, a Basel-based provider of software solutions for biopharmaceutical R&D, and will integrate the company into its Life Sciences segment. The acquisition expands Danaher’s R&D workflow capabilities by adding Genedata’s data-driven informatics and automation tools to accelerate drug discovery and development.

Genesis Drug Discovery & Development Acquires Comparative Biosciences (CBI)

August 5, 2020

Biotechnology

Genesis Drug Discovery & Development (GD3), a member of Genesis Biotechnology Group (GBG), has acquired Comparative Biosciences, Inc. (CBI), a Sunnyvale-based preclinical CRO. The acquisition adds GLP toxicology and safety pharmacology capabilities to GD3/GBG's integrated preclinical services, enabling end-to-end IND-enabling studies and expanding GD3's service offering.

General Datatech Acquires MDS Global IT

September 24, 2024

IT Services

General Datatech (GDT), a portfolio company of HIG Capital, has acquired MDS Global IT to expand GDT’s collaboration and contact center capabilities, including Cisco Unified Collaboration and Unified Contact Center Enterprise expertise. The acquisition adds MDS’s customers across healthcare, retail, banking, technology, and manufacturing to GDT’s client base and strengthens GDT’s global service delivery and scale. Kratos Capital acted as exclusive M&A advisor to MDS; the deal closed on September 24, 2024.

BioAgilytix Acquires Cambridge Biomedical

November 4, 2019

Healthcare Services

BioAgilytix, a GHO Capital portfolio company, has acquired Cambridge Biomedical, a Cambridge, Massachusetts–based clinical research organisation specializing in large-molecule bioanalysis. The deal expands BioAgilytix's laboratory capacity and capabilities (including CLIA/CAP/GLP capabilities and PCR/molecular suites), broadens its geographic footprint into the Boston/Cambridge biotech cluster, and strengthens its cell- and gene-therapy bioanalytical offerings.

Tesis Biosciences Acquires Genome Explorations

February 16, 2022

Biotechnology

Tesis Biosciences has acquired Genome Explorations to accelerate its clinical research and product development efforts in targeted genetic sequencing and precision medicine. The acquisition brings Genome Explorations’ genomic profiling and molecular diagnostics capabilities and clinical research staff into Tesis’ integrated platform to speed development of proprietary therapeutics and diagnostic products.

Boston Scientific Acquires BTG plc

August 19, 2019

Medical Devices

Boston Scientific Corporation completed its acquisition of BTG plc by scheme of arrangement, with BTG shareholders receiving 840 pence in cash per share. The purchase brings BTG’s interventional medicine portfolio, specialty pharmaceuticals and licensing business into Boston Scientific, strengthening its capabilities in interventional oncology and vascular therapies.